Cover Image
市場調查報告書

慢性心臟衰竭:全球臨床實驗檢討

Chronic Heart Failure Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 311767
出版日期 內容資訊 英文 273 Pages
訂單完成後即時交付
價格
Back to Top
慢性心臟衰竭:全球臨床實驗檢討 Chronic Heart Failure Global Clinical Trials Review, H1, 2017
出版日期: 2017年06月30日 內容資訊: 英文 273 Pages
簡介

心臟衰竭是指心臟無法將充足的血液送達其他器官的狀態所造成的。慢性心臟衰竭最常見的原因是由於心臟病發作造成左心室肌肉損傷,瘲狀為強烈的疲勞感、呼吸急促(有時是呼吸困難)、腳踝腫等。

本報告提供慢性心臟衰竭相關臨床研究的最新趨勢相關分析,提供您疾病治療方法概要,及臨床實驗的主要國家──G7各國及E7(新興7國)的臨床實驗數及實驗對象採用狀況,Phase、階段別的進展,有潛力的贊助商,各企業及研究機關的研究進展,有潛力的藥劑比較等資訊。

目錄

簡介

  • 慢性心臟衰竭
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5個國家的臨床實驗數量
    • 歐洲主要5個國家的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東及非洲的臨床實驗數量
    • 中南美及非洲的臨床實驗數量

G7各國臨床實驗數量:心臟血管系統臨床實驗數量上,慢性心臟衰竭臨床實驗數量所佔的比例

G7各國臨床實驗數量:Phase別

G7各國臨床實驗數量:各進展狀況

E7各國(新興7個國家)臨床實驗數量:心臟血管系統臨床實驗數量上,慢性心臟衰竭臨床實驗數量所佔的比例

E7各國(新興7個國家)臨床實驗數量:Phase別

E7各國(新興7個國家)臨床實驗數量:各進展狀況

Phase別臨床實驗數量

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗數量

試驗指標達成情況別臨床實驗數量

尚未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商的各類型臨床實驗數量

有潛力的贊助商

有潛力的藥劑

  • 最新臨床實驗資訊

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
    • Bayer AG
    • Orion Oyj
    • Novartis AG
    • Les Laboratoires Servier SAS
    • Zambon Company S.p.A.
    • 武田藥品工業
    • Galenica Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Alfred E. Tiefenbacher (GmbH & Co. KG)
  • 有代表性的大學·研究所的臨床實驗概要
    • Institut de Recherches Internationales Servier
    • Hull and East Yorkshire Hospitals NHS Trust
    • Fuwai Heart Hospital & Cardiovascular Institute
    • St. Marianna University School of Medicine
    • Federico II University
    • University Health Network
    • U.S. Department of Veterans Affairs
    • Duke University
    • Medical University of Silesia
    • 神戶大學

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4294CTIDB

GlobalData's clinical trial report, "Chronic Heart Failure Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Heart Failure clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 32
  • Prominent Sponsors 33
  • Top Companies Participating in Chronic Heart Failure Therapeutics Clinical Trials 35
  • Prominent Drugs 37
  • Latest Clinical Trials News on Chronic Heart Failure 38
  • Apr 10, 2017: Successful Interim Analysis of Efficacy Endpoint In Mesoblasts Phase 3 Trial for Chronic Heart Failure 38
  • Mar 31, 2017: Independent Data Monitoring Committee Initiates Process for Interim Analysis of Mesoblasts Phase 3 Chronic Heart Failure Trial 38
  • Clinical Trial Profile Snapshots 40

Appendix 271

  • Abbreviations 271
  • Definitions 271
  • Research Methodology 272
  • Secondary Research 272
  • About GlobalData 273
  • Contact Us 273
  • Source 273

List of Tables

List of Tables

  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Chronic Heart Failure Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Chronic Heart Failure Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Chronic Heart Failure Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Chronic Heart Failure Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Chronic Heart Failure Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 18
  • Chronic Heart Failure Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Chronic Heart Failure Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 22
  • Chronic Heart Failure Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Chronic Heart Failure Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Phase, 2017* 26
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

List of Figures

  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Chronic Heart Failure Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Chronic Heart Failure Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Chronic Heart Failure Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Chronic Heart Failure Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Chronic Heart Failure Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 17
  • Chronic Heart Failure Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Chronic Heart Failure Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Chronic Heart Failure to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 21
  • Chronic Heart Failure Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Chronic Heart Failure Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27
  • Chronic Heart Failure Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Chronic Heart Failure Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
  • GlobalData Methodology 272
Back to Top